Oncotarget

Research Papers:

The gain and loss of long noncoding RNA associated-competing endogenous RNAs in prostate cancer

Dianming Liu, Xuexin Yu, Shuyuan Wang, Enyu Dai, Leiming Jiang, Jing Wang, Qian Yang, Feng Yang, Shunheng Zhou and Wei Jiang _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:57228-57238. https://doi.org/10.18632/oncotarget.11128

Metrics: PDF 2592 views  |   HTML 2933 views  |   ?  


Abstract

Dianming Liu1,*, Xuexin Yu1,*, Shuyuan Wang1, Enyu Dai1, Leiming Jiang1, Jing Wang1, Qian Yang1, Feng Yang1, Shunheng Zhou1, Wei Jiang1

1College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China

*These authors have contributed equally to the work

Correspondence to:

Wei Jiang, email: jiangwei@hrbmu.edu.cn

Keywords: lncRNA, miRNA, ceRNA, prostate cancer, miRNA sponge

Received: March 03, 2016    Accepted: July 27, 2016    Published: August 09, 2016

ABSTRACT

Prostate cancer (PC) is one of the most common solid tumors in men. However, the molecular mechanism of PC remains unclear. Numerous studies have demonstrated that long noncoding RNA (lncRNA) can act as microRNA (miRNA) sponge, one type of competing endogenous RNAs (ceRNAs), which offers a novel viewpoint to elucidate the mechanisms of PC. Here, we proposed an integrative systems biology approach to infer the gain and loss of ceRNAs in PC. First, we re-annotated exon microarray data to obtain lncRNA expression profiles of PC. Second, by integrating mRNA and miRNA expression, as well as miRNA targets, we constructed lncRNA-miRNA-mRNA ceRNA networks in cancer and normal samples. The lncRNAs in these two ceRNA networks tended to have a longer transcript length and cover more exons than the lncRNAs not involved in ceRNA networks. Next, we further extracted the gain and loss ceRNA networks in PC. We found that the gain ceRNAs in PC participated in cell cycle, and the loss ceRNAs in PC were associated with metabolism. We also identified potential prognostic ceRNA pairs such as MALAT1-EGR2 and MEG3-AQP3. Finally, we inferred a novel mechanism of known drugs, such as cisplatin, for the treatment of PC through gain and loss ceRNA networks. The potential drugs such as 1,2,6-tri-O-galloyl-beta-D-glucopyranose (TGGP) could modulate lncRNA-mRNA competing relationships, which may uncover new strategy for treating PC. In summary, we systematically investigated the gain and loss of ceRNAs in PC, which may prove useful for identifying potential biomarkers and therapeutics for PC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 11128